Patient-Controlled Therapy of Breathlessness in Palliative Care: A New Therapeutic Concept for Opioid Administration?

被引:7
作者
Schmitz, Andrea [1 ,2 ]
Schulz, Christian [1 ]
Friebel, Uta [2 ]
Hohlfeld, Thomas [3 ]
Bausewein, Claudia [4 ]
机构
[1] Univ Dusseldorf, Fac Med, Interdisciplinary Ctr Palliat Med, Dusseldorf, Germany
[2] Univ Dusseldorf, Fac Med, Dept Anesthesiol, Dusseldorf, Germany
[3] Univ Dusseldorf, Fac Med, Inst Pharmacol & Clin Pharmacol, Dusseldorf, Germany
[4] Univ Munich, Dept Palliat Med, Munich Univ Hosp, Munich, Germany
关键词
Breathlessness; dyspnea; therapy; patient-controlled therapy; opioid; palliative care; CONTROLLED ANALGESIA; CANCER-PATIENTS; PAIN; MANAGEMENT; ONCOLOGY; SEDATION; DYSPNEA; GUIDELINES; CONVERSION; STATEMENT;
D O I
10.1016/j.jpainsymman.2015.10.015
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Context. Breathlessness is one of the most distressing symptoms experienced by patients with advanced cancer and noncancer diagnoses alike. Often, severity of breathlessness increases quickly, calling for rapid symptom control. Oral, buccal, and parenteral routes of provider-controlled drug administration have been described. It is unclear whether patient-controlled therapy (PCT) systems would be an additional treatment option. Objectives. To investigate whether intravenous opioid PCT can be an effective therapeutic method to reduce breathlessness in patients with advanced disease. Secondary aims were to study the feasibility and acceptance of opioid PCT in patients with refractory breathlessness. Methods. This was a pilot observational study with 18 inpatients with advanced disease and refractory breathlessness receiving opioid PCT. Breathlessness was measured on a self-reported numeric rating scale. Richmond Agitation Sedation Scale scores, Palliative Performance Scale scores, vital signs, and a self-developed patient satisfaction questionnaire were used for measuring secondary outcomes. Descriptive and interference analyses (Friedman test) and post hoc analyses (Wilcoxon tests and Bonferroni corrections) were performed. Results. Eighteen of 815 patients (advanced cancer; median age = 57.5 years [range 36-81]; 77.8% female) received breathlessness symptom control with opioid PCT; daily morphine equivalent dose at Day 1 was median = 20.3 mg (5.0-49.6 mg); Day 2: 13.0 mg (1.0-78.5 mg); Day 3: 16.0 mg (8.3-47.0 mg). Numeric rating scale of current breathlessness decreased (baseline: median = 5 [range 1-10]; Day 1: median = 4 [range 0-8], P < 0.01; Day 2: median = 4 [range 0-5], P < 0.01). Physiological parameters were stable over time. On Day 3, 12/12 patients confirmed that this mode of application provided relief of breathlessness. Conclusion. Opioid PCT is a feasible and acceptable therapeutic method to reduce refractory breathlessness in palliative care patients. (C) 2016 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:581 / 588
页数:8
相关论文
共 39 条
  • [1] Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea
    Abernethy, AP
    Currow, DC
    Frith, P
    Fazekas, BS
    McHugh, A
    Bui, C
    [J]. BRITISH MEDICAL JOURNAL, 2003, 327 (7414): : 523 - 526
  • [2] Palliative Care Training in Surgical Oncology and Hepatobiliary Fellowships: A National Survey of the Fellows
    Amini, Albert
    Miura, John T.
    Larrieux, Greg
    Tsai, Susan
    Turaga, Kiran K.
    Christians, Kathleen K.
    Brasel, Karen J.
    Gamblin, T. Clark
    Weissman, David E.
    Nattinger, Ann B.
    Johnston, Fabian M.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2015, 22 (06) : 1761 - 1767
  • [3] Bandura A, 1994, Encyclopedia of mental health, V4th, DOI DOI 10.1002/9780470479216.CORPSY0836
  • [4] Interventions for alleviating cancer-related dyspnea: A systematic review and meta-analysis
    Ben-Aharon, Irit
    Gafter-Gvili, Anat
    Leibovici, Leonard
    Stemmer, Salomon M.
    [J]. ACTA ONCOLOGICA, 2012, 51 (08) : 996 - 1008
  • [5] Brant Jeannine M, 2013, J Adv Pract Oncol, V4, P415
  • [6] The Richmond Agitation-Sedation Scale modified for palliative care inpatients (RASS-PAL): a pilot study exploring validity and feasibility in clinical practice
    Bush, Shirley H.
    Grassau, Pamela A.
    Yarmo, Michelle N.
    Zhang, Tinghua
    Zinkie, Samantha J.
    Pereira, Jose L.
    [J]. BMC PALLIATIVE CARE, 2014, 13
  • [7] European Association for Palliative Care (EAPC) recommended framework for the use of sedation in palliative care
    Cherny, Nathan I.
    Radbruch, Lukas
    [J]. PALLIATIVE MEDICINE, 2009, 23 (07) : 581 - 593
  • [8] Evidence-based interventions to improve the palliative care of pain, dyspnea, and depression at the end of life: A clinical practice guideline from the American college of physicians
    Claseem, Amir
    Snow, Vincenza
    Shekelle, Paul
    Casey, Donald E., Jr.
    Cross, J. Thomas, Jr.
    Owens, Douglas K.
    [J]. ANNALS OF INTERNAL MEDICINE, 2008, 148 (02) : 141 - 146
  • [9] Conversion of Karnofsky Performance Status (KPS) and Eastern Cooperative Oncology Group Performance Status (ECOG) to Palliative Performance Scale (PPS), and the Interchangeability of PPS and KPS in Prognostic Tools
    de Kock, Ingrid
    Mirhosseini, Mehrnoush
    Lau, Francis
    Thai, Vincent
    Downing, Michael
    Quan, Hue
    Lesperance, Mary
    Yang, Ju
    [J]. JOURNAL OF PALLIATIVE CARE, 2013, 29 (03) : 163 - 169
  • [10] Patient-Controlled Analgesia in Patients with Advanced Cancer. Should Patients Be in Control?
    Dev, Rony
    Del Fabbro, Egidio
    Bruera, Eduardo
    [J]. JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2011, 42 (02) : 296 - 300